This study explored the impact of proton pump inhibitors (PPIs) on lumen-apposing metal stent (LAMS) occlusion rates in patients undergoing pancreatic necrosectomy for walled-off necrosis (WON). LAMS are used to drain infected or necrotic fluid collections in the pancreas, offering a minimally invasive alternative to surgical approaches.
This study explored the impact of proton pump inhibitors (PPIs) on lumen-apposing metal stent (LAMS) occlusion rates in patients undergoing pancreatic necrosectomy for walled-off necrosis (WON). LAMS are used to drain infected or necrotic fluid collections in the pancreas, offering a minimally invasive alternative to surgical approaches. However, complications like stent blockage can occur, requiring additional procedures such as endoscopic necrosectomy to remove debris.
The study analyzed data from 893 patients and 967 LAMS placements across multiple European centers. After excluding intermittent PPI users and incomplete records, 768 stents were evaluated. Among these, 577 patients were on continuous PPIs, while 191 did not use PPIs. Results showed that PPI use significantly increased LAMS occlusion rates (30% in PPI users vs. 23% in non-users) and the need for endoscopic necrosectomies. Statistical models confirmed that continuous PPI use heightened the risk of stent blockage (OR 0.61, P = 0.04 for non-PPI users) and necrosectomy (IRR 0.8, P = 0.006). A dose-dependent and compound-specific effect of PPIs was also observed.
PPIs may contribute to stent occlusion by altering gastric pH, which can affect the composition of pancreatic fluid and promote debris accumulation. Importantly, avoiding PPIs did not increase bleeding risks or other complications, suggesting routine PPI use during LAMS placement should be reconsidered to improve outcomes.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.